Prof Maurizio D’Incalci has been working for more than 30 years investigating the mode of action and pharmacological properties of anticancer agents. A significant part of his research has been devoted to compounds acting by causing DNA damage and perturbations of the cell cycle and of transcriptional regulation. His work has been instrumental in developing some anticancer drugs that have been successfully introduced into the clinic including temozolomide, etoposide, altretamine and trabectedin.
In his research, he has integrated knowledge of the mechanisms of action of drugs with pharmacokinetic and pharmacodynamic information. This juxtaposition is most relevant for rational and effective clinical drug development. His team has been very active in applying newly developed technologies to ascertain the tumor distribution of the drug both in preclinical models and in cancer patients. A great part of the research effort of his team has been directed to establish appropriate preclinical cellular and in vivo tumor models that mimic human neoplastic diseases.
In 2007, he was made visiting professor of the UK Open University. He has been chairman of the Research Division of the European Organization for Research and Treatment of Cancer (EORTC) and member of many grant evaluation bodies instituted by Cancer Research UK and UK Department of Health and Social Security. At present he is chairman of the Mario Negri Gynecologic Oncology Group (MaNGO), member of the Scientific Advisory Board of the UK charity Target Ovarian Cancer, and president of Società Italiana di Cancerologia. Since March 2021, he is professor of pharmacology at Humanitas University and Group Leader at Humanitas Research Hospital.
As of January, 2023, scientific publications include 590 peer-reviewed articles in journals covered by the JCR®. His H-index (Scopus) is 72.